Description

Alexan (cytarabine) solution 50 mg/ml. 20 ml. (1000 mg.) vial №1

Ingredients

Active ingredient: Cytarabine. Other ingredients: sodium hydroxide, hydrochloric acid, and water for injection.

Dosage

Dosage: The recommended dose of Alexan is determined by the patient’s body surface area and the condition being treated. It is administered intravenously by a healthcare professional.

Indications

Indications: Alexan is indicated for the treatment of various types of leukemia, including acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).

Contraindications

Contraindications: Alexan should not be used in patients with known hypersensitivity to cytarabine or any of the other ingredients in the formulation.

Directions

Administration: Alexan should only be administered by healthcare professionals experienced in the use of cytotoxic chemotherapy agents. The solution should be visually inspected for particulate matter and discoloration before administration.

Scientific Evidence

Cytarabine, the active ingredient in Alexan, is a cytosine analog that interferes with the synthesis of DNA. This disruption leads to the inhibition of DNA polymerase, ultimately causing cell death. Studies have shown that cytarabine is effective in inducing remission in patients with leukemia.

Research published in the Journal of Clinical Oncology has demonstrated the efficacy of cytarabine in combination with other chemotherapeutic agents in improving overall survival rates in patients with AML. The study highlighted the importance of cytarabine in the treatment of this aggressive form of leukemia.

Additional Information

• Alexan should be stored at controlled room temperature between 20°C to 25°C (68°F to 77°F).
• Patients should be monitored regularly for bone marrow suppression and other potential adverse reactions during treatment with Alexan.